Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease

Annals of Internal Medicine

Volumn 169, Issue 2, 2018, Pages 133-

  Oshima, Yasuo ^a   Hagino, Noboru ^b   Hara, Masumi ^c   Ohfuji, Takashi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c TEIKYO UNIVERSITY HOSPITAL   (Japan)

^d National Center for Global Health and Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; LETTER; PRIORITY JOURNAL; HUMAN; NEOPLASM;

IPILIMUMAB; MONOCLONAL ANTIBODY;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IPILIMUMAB; NEOPLASMS;

EID: 85050381823     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L18-0208     Document Type: Letter

References (1)

1. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018; 168:121-30. [PMID: 29297009] doi: 10.7326/M17-2073